Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines. The company is developing VDA-1102 CTCL which is in phase 2 clinical trials for the treatment of cutaneous T cell lymphoma (CTCL); and VDA-1102 Ointment, an anti-neoplastic agent that is in phase 2B clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that is in preclinical stage for use in the treatment of solid tumors. Vidac Pharma Holding Plc was founded in 2012 and is headquartered in London, the United Kingdom.